CN100402093C - Medicine used in medical breath diagnosis - Google Patents

Medicine used in medical breath diagnosis Download PDF

Info

Publication number
CN100402093C
CN100402093C CNB021346232A CN02134623A CN100402093C CN 100402093 C CN100402093 C CN 100402093C CN B021346232 A CNB021346232 A CN B021346232A CN 02134623 A CN02134623 A CN 02134623A CN 100402093 C CN100402093 C CN 100402093C
Authority
CN
China
Prior art keywords
medicine
marked
chemical compound
carbon atom
abundance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021346232A
Other languages
Chinese (zh)
Other versions
CN1478551A (en
Inventor
马永健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhang Houde
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB021346232A priority Critical patent/CN100402093C/en
Publication of CN1478551A publication Critical patent/CN1478551A/en
Application granted granted Critical
Publication of CN100402093C publication Critical patent/CN100402093C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a medical diagnosis technology and particularly discloses a medicine for medical breath diagnosis. The medicine for medical breath diagnosis comprises a <13>C labeled compound which is made into a certain dosage form. The present invention is characterized in that at least one labeling position in the <13>C labeled compound has the abundance of 50 to 95%. Because the medicine for medical breath diagnosis provided by the present invention is prepared by a compound with lower <13>C abundance, the medicine for medical breath diagnosis largely shortens the preparation period, reduces the production cost, and makes the popularity and the use of stable isotope medicine breath diagnosis realized.

Description

The medicine that is used for medical breath diagnosis
Technical field
The present invention relates to medical diagnostic techniqu, be specifically related to be used for the medicine of medical breath diagnosis.
Background technology
Utilize the stable isotopic tracer technology, realize medical diagnosis, accepted by numerous doctors and patient day by day by breath test.Prior art adopts abundance 99% 13C isotopic labeling medicine, its manufacturing cycle is long, and the expense height makes that the cost of this expiration experiment is too high, is difficult to be popularized.
Summary of the invention
The technical problem to be solved in the present invention is, the novel medicine that is used for medical breath diagnosis is provided, and has short production cycle and lower preparation expense, and, can guarantee the accuracy of medical breath diagnosis.
The above-mentioned technical problem of the present invention is to solve like this, construct a kind of medicine that is used for medical breath diagnosis, comprises making certain dosage form 13The C labelled compound is characterized in that, at least one mark position of described chemical compound 13The C abundance is 50-95%, prepares the raw material of described chemical compound 13C directly directly obtains by the mode of low temperature distillation, chromatographic isolation, electromagnetic separation, isotope diffusion, biological concentration or its combination.
In said medicine, described chemical compound is a kind of in the following chemical compound: 13C-carbamide, 13C-erythromycin, 13The C-phenylalanine, 13The C-corn starch, 13The C-Semen Maydis oil, 13The C-tripalmitin, 13C-sucrose, 13The C-lactose, 13The C-acetas, 13C-acetic acid, 13C-is sad, 13The C-caprylate, 13C-carbonic acid, 13The C-glycine, 13C-glycerol cholic acid, 13C-ketone group isocaproic acid, 13C-ethanol, 13The C-valproic acid or 13The C-fatty acid.
In said medicine, described chemical compound and mark position thereof are a kind of in following: 3-( 13C) methyl caffeine, wherein 13C is marked on the carbon atom of the methyl that is connected with 3 carbon atoms of caffeine; N, n-( 13C) dimethylamino is than woods, 13C is marked on the carbon atom in two methyl that are connected with nitrogen-atoms; 13C methoxyl group Mei Shaxiding, 13C is marked on the carbon atom of methoxyl group; (1- 13C) ethyoxyl-phenacetin, 13C is marked on 1 carbon atom in the ethyoxyl; (1,1,1- 13C) triolein, 13C is marked on three 1 carbon atoms in the glycerol; (1,1,1- 13C) tricaprylin, 13C is marked on three 1 carbon atoms in the glycerol; 13The C-xylose or 13C-pentose (1- 13C), wherein, 13In the C-xylose 13C is marked on 1 carbon atom; 13C-pentose (1- 13C) in 13C is marked on 1 carbon atom.
In said medicine, prepare the raw material of described chemical compound 13C be directly by low temperature distillation, chromatographic isolation, electromagnetic separation, isotope diffusion, biological concentration or and the mode of combination directly obtain.
According to the medicine that is used for medical breath diagnosis provided by the invention, described certain dosage form is capsule or tablet, also comprises the container that is used to place described capsule or tablet, and described container can be box, bottle, sack.
According to the medicine that is used for medical breath diagnosis provided by the invention, described certain dosage form is a solution, also comprises the container that is used to place described solution, and described container can be a bottle.
According to the medicine that is used for medical breath diagnosis provided by the invention, in described chemical compound specific markers position 13The C abundance is 60-90%.
According to the medicine that is used for medical breath diagnosis provided by the invention, in described chemical compound specific markers position 13The C abundance is 60-85%.
Enforcement owing to adopt low abundance, therefore can be shortened manufacturing cycle according to the medicine that is used for medical breath diagnosis provided by the invention greatly, reduces production costs, and makes the popularization and application of medical breath diagnosis become possibility.
The specific embodiment
Embodiment 1:
The employing chemical compound is 13C-carbamide, abundance are 58%, carry out breath test simultaneously with traditional 99% abundance product, have identical diagnostic accuracy, and this chemical compound is to adopt 13The C abundance is that 58% carbon monoxide is obtained as raw material is synthetic, and this raw material is to obtain in the middle of traditional low temperature distillation preparation process, also can obtain by electromagnetic separation, chromatographic isolation combination technique.Like this, its preparation cost will be significantly less than by with abundance 99% 13C-carbamide dilutes and obtains 58% 13The required cost of equivalent medicine of C abundance because prepare 99% and the cost of above abundance chemical compound be very expensive.Further, said medicine can be made into capsule, in batches capsulation in sack, the person that needs the breath test, as long as take out wherein capsule obey into, every the certain hour detection of exhaling, carry out medical diagnosis on disease according to detected result.
Embodiment 2:
The employing chemical compound is 13C-aminophenazone, abundance are 95%, and the process check has concordance with the diagnostic result of traditional 99% abundance product, because the raw material that this medicine adopts is an abundance 95% 13C-chemical compound (this chemical compound can be carbon monoxide, carbon dioxide, brium carbonate etc.), utilize electromagnetic separation and chromatographic isolation combination technique to obtain, also can in the middle of traditional excessively low temperature distillation preparation process, it be obtained, so expense is significantly less than by preparing 13C abundance 99% 13The C-aminophenazone dilutes and obtains abundance 95% 13The needed cost of C-aminophenazone.Said medicine is made into tablet, and in batches tablet medicine is packaged in the bottle again, during breath test, therefrom takes out under several clothes and gets final product.
Embodiment 3:
Successively adopt chemical compound and molecular formula thereof as follows, in the round bracket be 13The ad-hoc location of C labelling: 1, 13C-carbamide [ 13C-Urea]
3, 13C-aminophenazone [Aminopyrine (n, n-dimethyl- 13C)]
4, 13C-Mei Shaxiding [Methacetin (methoxy- 13C)]
5, 13C-phenacetin [Phenacetin (ethoxy-1- 13C)]
6, 13C-erythromycin [ 13C-Erythromycin]
7, 13The C-phenylalanine [ 13C-Phenylalanine]
8, 13The C-triolein [Triolein (1,1,1- 13C)]
9, 13The C-tricaprylin [Trioctanoin (1,1,1- 13C)]
10, 13The C-corn starch [ 13C-Maize Starch]
11, 13The C-Semen Maydis oil [ 13C-Maize Oil]
12, 13C-triglyceride (blended) [ 13C-Triglycerides (mixed)]
13, 13The C-tripalmitin [ 13C-Tripalmitin]
14, 13The C-xylose or 13C-pentose [D-Xylose (1- 13C)]
15, 13C-sucrose [ 13C-Sucrose]
16, 13The C-lactose [ 13C-Lactose]
17, 13The C-acetas [ 13C-Acetate]
18, 13C-acetic acid [ 13C-Acetic Acid]
19, 13C-sad [ 13C-Octanoate]
20, 13The C-caprylate [ 13C-Octanoic Acid]
21, 13C-carbonic acid [ 13C-Hydrogen Carbonate]
22, 13The C-glycine [ 13C-Glycine]
23, 13C-glycerol cholic acid [ 13C-Glycocholic Acid]
24, 13C-ketone group isocaproic acid [ 13C-Ketoisocaproic Acid]
25, 13C-ethanol [ 13C-Ethanol]
26, 13The C-valproic acid [ 13C-Valproic Acid]
27, 13The C-fatty acid [ 13C-Fatty Acid]
28, 13C-caffeine [Caffeine (3-methyl- 13C)]
29, 13C-aminophenazone [Aminopyrine (n, n-dimethyl- 13C)]
30, 13C-Mei Shaxiding [Methacetin (methoxy- 13C)]
31, 13C-phenacetin [Phenacetin (ethoxy-1- 13C)]
32, 13The C-triolein [Triolein (1,1,1- 13C)]
33, 13The C-tricaprylin [Trioctanoin (1,1,1- 13C)]
34, 13The C-corn starch [ 13C-Maize Starch]
35, 13The C-tripalmitin [ 13C-Tripalmitin]
36, 13The C-xylose or 13C-pentose [D-Xylose (1- 13C)]
Experiment shows which kind of dosage form no matter medicine of the present invention adopt, because its synthetic raw material that adopts, promptly 13The C abundance is the carbon compound of 50-95%, all directly directly obtains by the mode of low temperature distillation, chromatographic isolation and electromagnetic separation or isotope diffusion, biological concentration and combination thereof, therefore, can reduce greatly 13The preparation cost of C labelling breath test medicine, thus make stable isotope breath diagnosis technology obtain higher generalization and universal.

Claims (7)

1. the cold labeling medicine that is used for medical breath diagnosis comprises and makes certain dosage form 13The C labelled compound is characterized in that, at least one mark position of described chemical compound 13The C abundance is 50-95%, prepares the raw material of described chemical compound 13C directly directly obtains by the mode of low temperature distillation, chromatographic isolation, electromagnetic separation, isotope diffusion, biological concentration or its combination.
2. according to the described medicine of claim 1, it is characterized in that described chemical compound is a kind of in the following chemical compound: 13C-carbamide, 13C-erythromycin, 13The C-phenylalanine, 13The C-corn starch, 13The C-Semen Maydis oil, 13The C-tripalmitin, 13C-sucrose, 13The C-lactose, 13The C-acetas, 13C-acetic acid, 13C-is sad, 13The C-caprylate, 13C-carbonic acid, 13The C-glycine, 13C-glycerol cholic acid, 13C-ketone group isocaproic acid, 13C-ethanol, 13The C-valproic acid or 13The C-fatty acid.
3. according to the described medicine of claim 1, it is characterized in that described chemical compound and mark position thereof are a kind of in following: 3-( 13C) methyl caffeine, wherein 13C is marked on the carbon atom of the methyl that is connected with 3 carbon atoms of caffeine; N, n-( 13C) dimethylamino is than woods, 13C is marked on the carbon atom in two methyl that are connected with nitrogen-atoms; 13C methoxyl group Mei Shaxiding, 13C is marked on the carbon atom of methoxyl group; (1- 13C) ethyoxyl-phenacetin, 13C is marked on 1 carbon atom in the ethyoxyl; (1,1,1- 13C) triolein, 13C is marked on three 1 carbon atoms in the glycerol; (1,1,1- 13C) tricaprylin, 13C is marked on three 1 carbon atoms in the glycerol; 13The C-xylose or 13C-pentose (1- 13C), wherein, 13In the C-xylose 13C is marked on 1 carbon atom; 13C-pentose (1- 13C) in 13C is marked on 1 carbon atom.
4. according to any one described medicine among the claim 1-3, it is characterized in that described certain dosage form is capsule or tablet, also comprises the container that is used to place described capsule or tablet, described container is box, bottle, sack.
5. according to the described medicine of claim 4, it is characterized in that described certain dosage form is a solution, also comprises the container that is used to place described solution, described container is a bottle.
6. according to the described medicine of claim 4, it is characterized in that, in described chemical compound specific markers position 13The C abundance is 60-90%.
7. according to the described medicine of claim 4, it is characterized in that, in described chemical compound specific markers position 13The C abundance is 60-85%.
CNB021346232A 2002-08-26 2002-08-26 Medicine used in medical breath diagnosis Expired - Fee Related CN100402093C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021346232A CN100402093C (en) 2002-08-26 2002-08-26 Medicine used in medical breath diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021346232A CN100402093C (en) 2002-08-26 2002-08-26 Medicine used in medical breath diagnosis

Publications (2)

Publication Number Publication Date
CN1478551A CN1478551A (en) 2004-03-03
CN100402093C true CN100402093C (en) 2008-07-16

Family

ID=34145886

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021346232A Expired - Fee Related CN100402093C (en) 2002-08-26 2002-08-26 Medicine used in medical breath diagnosis

Country Status (1)

Country Link
CN (1) CN100402093C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512258B2 (en) * 2005-11-11 2013-08-20 Exalenz Bioscience Ltd. Breath test device and method
CN101881763A (en) * 2009-10-27 2010-11-10 天津赛德生物制药有限公司 Urea breath detection kit for detecting stomach helicobacter pylori
EP2887066B1 (en) * 2012-08-20 2020-08-05 Otsuka Pharmaceutical Co., Ltd. Composition for use in a method for measuring carbohydrate metabolism ability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101583A (en) * 1996-09-25 1998-04-21 Tokyo Gas Co Ltd Diabetes diagnostic agent
WO1999056790A2 (en) * 1998-05-06 1999-11-11 Isotechnika, Inc. 13c glucose breath test for the diagnosis of diabetes
CN1249036A (en) * 1997-03-11 2000-03-29 菲舍尔分析仪器有限公司 Carbon isotope analyser
CN1277545A (en) * 1997-09-11 2000-12-20 奥莱登医学有限公司 Breath test analyser

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101583A (en) * 1996-09-25 1998-04-21 Tokyo Gas Co Ltd Diabetes diagnostic agent
CN1249036A (en) * 1997-03-11 2000-03-29 菲舍尔分析仪器有限公司 Carbon isotope analyser
CN1277545A (en) * 1997-09-11 2000-12-20 奥莱登医学有限公司 Breath test analyser
WO1999056790A2 (en) * 1998-05-06 1999-11-11 Isotechnika, Inc. 13c glucose breath test for the diagnosis of diabetes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
0.75uCi胶囊法14C-UBT诊断幽门螺杆菌感染. 张厚德，马永健.胃肠病学和肝病学杂志，第6卷第3期. 1997
0.75uCi胶囊法14C-UBT诊断幽门螺杆菌感染. 张厚德，马永健.胃肠病学和肝病学杂志，第6卷第3期. 1997 *
MAT-251质谱计在13CO2呼气检查法中的应用. 文启彬.质谱学报，第17卷第2期. 1996
MAT-251质谱计在13CO2呼气检查法中的应用. 文启彬.质谱学报，第17卷第2期. 1996 *
呼气试验：在消化病临床上应用和评价. 徐克成.华人消化杂志，第6卷. 1998
呼气试验：在消化病临床上应用和评价. 徐克成.华人消化杂志，第6卷. 1998 *
在诊断HP的14C-UBT中14C-尿素的最低有效活度的研究. 马永健，张厚德，陈观榕，叶平.胃肠病学和肝病学杂志，第6卷第2期. 1997
在诊断HP的14C-UBT中14C-尿素的最低有效活度的研究. 马永健，张厚德，陈观榕，叶平.胃肠病学和肝病学杂志，第6卷第2期. 1997 *

Also Published As

Publication number Publication date
CN1478551A (en) 2004-03-03

Similar Documents

Publication Publication Date Title
Evans et al. A bioorthogonal 68 Ga-labelling strategy for rapid in vivo imaging
Ding et al. Chiral drugs: comparison of the pharmacokinetics of [11C] d-threo and L-threo-methylphenidate in the human and baboon brain
CN102015725B (en) Forms of rifaximin and uses thereof
US20070166227A1 (en) Crowned dithiocarbamate metal complexes and methods for their use
CN103269587A (en) New forms of rifaximin and uses thereof
CN102834398A (en) Forms of rifaximin and uses thereof
CN103524427B (en) Preparation method as well as application of trimethoprem hapten
CN100402093C (en) Medicine used in medical breath diagnosis
CN108938626A (en) A kind of good and highly-safe Carbazochrome sodium sulfonate pharmaceutical composition and its preparation method and application of stability
CN101003540A (en) Anti infectious compound and usage
CN108690129A (en) A kind of hemp antigen and preparation method
US20150297759A1 (en) Novel fluorine-18 labeled rhodamine derivatives for imaging with positron emission tomography
CN102070539A (en) 1-oxo-2-methyl-3-(1-ethoxyl)-quinoxaline and preparation method and application thereof
Kronauge et al. Synthesis and identification of the monocation Tc (CPI) 6+ in Tc (CNC (CH3) 2COOCH3) 6Cl and its hydrolysis products
CN109157527A (en) A kind of Irbesartan Capsules and preparation method thereof
CN110935040A (en) Kit for preparing prostate cancer molecular probe and application
CN113773283B (en) Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof
CN112390760B (en) FAK-targeting compound and preparation method and application thereof
AU626702B2 (en) Radioactive diagnostic agent
Abounassif et al. Analytical profile of mexiletine hydrochloride
RU2492171C2 (en) Crystalline form of eszopiclone, its composition, preparation and application
CN101003543A (en) Anti infectious compound and usage
EP3056221A1 (en) Spect radionuclide-labeled trimeric cyclic rgd peptide, preparation method thereof and imaging method thereof
CN101543511A (en) Pressed pharmaceutical composition containing medicinal charcoal and polyethyleneglycol
Ackermann et al. Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SHENZHEN CITY XIANYA BIOLOGICAL SCIENCE CO., LTD.

Free format text: FORMER OWNER: MA YONGJIAN

Effective date: 20090814

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090814

Address after: Guangdong city of Shenzhen province Nanshan District Nanxin East Road and Taoyuan North Road Xiamen 15A1 SOHO

Patentee after: Zhang Houde

Address before: Room 16, building 302, Liwan garden, Nanshan District, Shenzhen, Guangdong

Patentee before: Ma Yongjian

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080716

Termination date: 20200826